WL Gore and Associates launches new Viabahn option in Europe

WL Gore and Associates (Gore) has launched its new Viabahn Endoprosthesis stent-graft for a lower profile delivery system in Europe.

The new medical device received CE Mark approval late last year and is intended for use among peripheral artery disease patients, percutaneously treating the condition by relining the native vessel.

It features Propaten Bioactive Surface technology, which makes the process of interacting with the bloodstream more effective, while it has also been designed with a reduced delivery profile for greater flexibility of use.

The standard Gore Viabahn Endoprosthesis was originally approved in Europe in 2008 and is the successor to the Hemobahn Endoprosthesis, introduced in 1996.

Erin Hutchinson, an associate with Gore's peripheral vascular business, said: "As every clinical case is different, Gore is committed to providing physicians globally with innovative tools to successfully treat their patients."

Earlier this month, the firm announced that its Gore C3 Delivery System has been used in a clinical setting to deploy the Excluder AAA Endoprosthesis for the first time.